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Renal artery revascularization: Outcomes stratified
by indication for intervention
Virendra I. Patel, MD, Mark F. Conrad, MD, Christopher J. Kwolek, MD, Glenn M. LaMuraglia, MD,
Thomas K. Chung, MS, and Richard P. Cambria, MD, Boston, Mass
Objectives: Application of endovascular therapy has led to increasing rates of renal artery intervention with unclear effect
on hypertension (HTN) and/or renal salvage (RS). We evaluated the role of procedure indication on outcomes of both
open (OR) and percutaneous (PR) revascularization.
Methods: Retrospective review of all consecutive renal artery interventions performed from January 1, 2002 to December
31, 2006 was conducted. OR patients were included for analysis only if independent renovascular indications for
revascularization existed.
Results: Forty-sevenOR and 203 PR (97% stent) patients were treated with 98% initial technical success. Patients with OR
were younger (65 11 vs 72 9; P< .01), on more blood pressure (BP) medications (2.3 1.2 vs 1.8 1.2; P< .05),
hadmore peripheral arterial disease (75% vs 37%; P< .01), and higher baseline creatinine (2.2 1.6mg% vs 1.8 1mg%;
P< .05). Indications for PR were HTN in 46% and RS in 54%, and indications for OR were HTN in 51% and RS in 49%
of cases. PR was unilateral in 169 (83%) and bilateral in 44/203 (17%). OR consisted of bypass in 26 (53%) and
endarterectomy in 21/47 (47%) with 20 (43%) bilateral procedures. Peri-procedural complications were different (P <
.01) and more frequent in OR (23% vs 12%). Survival was similar at three years (72% 4% PR vs 71% 9% OR; P .9).
Assisted patency was similar (P  .6) at one (94%  2% PR vs 97%  3% OR) and three years (90%  3% PR vs 91% 
5% OR). One year (97%  1% PR vs 97%  3% OR) and three year (93%  3% PR vs 91%  7% OR) freedom from
reintervention was similar (P  .8). Clinical outcomes showed patients with OR and PR having similar rates of cure or
improvement in BP (76% PR vs 90% OR; P  .1) and favored OR with stable or improved renal function (97% vs 89%;
P < .01) by the first postoperative visit. Hypertension control remained similar (P  .2) in both groups with
cure/improvement in BP in 74% of PR and 89% of OR patients at one year. OR remained durable in regards to renal
salvage with 52% of OR patients having improved renal function compared with 24% of PR (P< .01) patients at one year.
At one year, BP control was achieved if treatment indication was HTN in 100% (18/18) of OR patients and 74% (46/63)
(P  .04) of those having PR. Renal function stabilized or improved in 16/19 (85%) of OR and 70/81 (86%) of PR
patients when performed for RS (P  .4).
Conclusions: PR and OR are similarly efficacious for treatment of HTN associated with renal artery stenosis. While
immediate and long-term outcomes favor OR for RS, this may impart from the triage of patients more likely to benefit
from renal artery revascularization to OR. (J Vasc Surg 2009;49:1480-9.)Atherosclerotic renal artery stenosis (RAS) is associated
with acute coronary syndromes, stroke, and increased long-
term mortality corresponding to the degree of renal artery
stenosis.1-3 The incidence of RAS is currently as high as
6.8% in adults over the age of 65 and may contribute to the
development of end stage renal disease in as many as 15% to
25% of patients beginning dialysis each year.4,5 We and
others have shown that open surgical renal artery revascu-
larization results in preservation of renal function and con-
trol of hypertension in appropriately selected individuals
with RAS.6-9 Percutaneous transluminal angioplasty and
stenting of atherosclerotic renal artery stenosis has recently
demonstrated efficacy with success rates approaching 98%
and with a considerable decrease in procedural morbidity
and mortality compared to surgery.10,11 This, in turn, has
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1480led to widespread application of endovascular therapy, and
increasing rates of renal artery intervention.12
Despite the enthusiasm for percutaneous renal artery
revascularization, several randomized controlled trials have
failed to demonstrate a benefit on blood pressure control
when compared with aggressive medical therapy.13-15 It is
generally acknowledged that the evidence base supporting
widespread application of renal artery intervention is at best
weak, and at worst non-existent.16 However, it has been
demonstrated that benefits,17-19 even to the extent of
discontinuation of renal replacement therapy, are seen in
certain patients.6-9 The clinical conundrum of predicting
which patients will benefit from treatment of renal artery
stenosis is as yet unresolved.
Long term clinical outcomes of renal artery revascular-
ization with respect to both blood pressure control and
renal function preservation are as yet unclear, due to widely
discrepant clinical presentations of RAS, confounding dis-
ease processes often including a degree of fixed irreversible
renal parenchymal damage, and variable reporting criteria.
The purpose of this study was to evaluate the clinical
success of renal artery revascularization using standardized
reporting criteria and to evaluate the role of procedure
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intended outcomes of both open (OR) and percutaneous
(PR) renal artery revascularization.
MATERIALS AND METHODS
We performed a retrospective analysis of all consecutive
renal artery revascularizations performed at the Massachu-
setts General Hospital from January, 2002 through De-
cember, 2006. Two hundred twenty-four patients were
treated with percutaneous renal artery revascularization
(PR) and 105 patients were treated with open revascular-
ization (OR) during the study period. Significant renal
artery stenosis was defined as a stenosis of 75% or greater as
measured using digital subtraction angiography (DSA),
computed tomographic angiography (CTA), or magnetic
resonance angiography (MRA). Indications for revascular-
ization included hypertension (HTN) in patients with un-
controlled blood pressure in the setting of multiple anti-
hypertensive agents or escalating blood pressure in the
setting of previously controlled hypertension on three or
more agents. The indication for renal revascularization was
RS in the setting of ischemic nephropathy with Cr  1.5
mg/dL or significant stenosis to a single functioning kid-
ney or if revascularization was required to the entire func-
tioning renal mass irrespective of baseline renal function.
Indications for revascularization vary and in many instances
include a combination of HTN and RS, however we de-
fined the indication as HTN or RS depending on the more
pressing clinical indication at the time of revascularization
or as defined by the operative note. Secondary interven-
tions for previously treated vessels were excluded from
analysis. In the OR group, patients undergoing renal artery
revascularization in the context of concomitant aortic re-
construction or aortic de-branching procedures and with-
out specific indications for renal artery revascularization
were excluded. Of all PR patients, 203 patients underwent
primary intervention and were included in the final analysis.
Of all OR patients, 47 patients had independent renovas-
cular indications for renal artery revascularization and were
therefore included for final analysis. The study was de-
signed to evaluate and compare the overall and indication-
specific outcomes of the OR and PR groups.
Demographic data and risk factors evaluated in our
study included age, gender, pre-operative serum creatinine,
presence of concomitant peripheral arterial and coronary
artery disease, smoking, diabetes mellitus, hypertension,
chronic renal insufficiency, hypercholesterolemia, acute re-
nal failure (see below), and preoperative systolic and dia-
stolic blood pressure (mmHg). The most recent serum
creatinine (mg per deciliter, mg/dL) and blood pressure
(mmHg) prior to renal artery revascularization were used as
baseline data. Coronary artery disease (CAD) was defined
as a history of myocardial infarction, positive cardiac stress
test, or previous percutaneous or open surgical coronary
artery revascularization. Peripheral arterial disease was de-
fined as a history of intermittent claudication, ischemic rest
pain, ischemic gangrene or tissue loss, or a previous history
of percutaneous or open surgical revascularization of thelower extremity arterial circulation. Acute renal failure was
defined as a doubling of serum creatinine or serial increase
in serum creatinine with or without oliguria or anuria
occurring over seven days or less.
Technical factors studied included unilateral vs bilateral
intervention and factors related to the mode of renal artery
revascularization. For percutaneous revascularization an-
gioplasty vs angioplasty and stenting, contrast volume, and
procedural success defined as completion of the procedure
with less than 30% residual stenosis are reported. Open
surgery analysis included bypass vs endarterectomy, con-
comitant aortic surgery, and the number of bilateral proce-
dures. The technical success of OR was evaluated as part of
the operative procedure with evaluation of pulses and
Doppler signals intraoperatively following removal of
clamps and the re-establishment of renal artery flow. In the
perioperative setting, urine output and serum creatinine
were closely followed as indirect measures of successful
revascularization. Postoperative complications evaluated in
the present study included the number of procedures with-
out any postoperative complications, death, hematoma,
contrast nephropathy, pseudo aneurysm, pneumonia, hep-
arin induced thrombocytopenia, operative re-exploration,
and wound infection. Postoperative complications were
referable to adverse events occurring within 30 days of the
index procedure. Contrast nephropathy was defined as any
temporal and transient elevation in serum creatinine greater
than 50% from baseline with or without an associated
decrease in urine output following percutaneous renal re-
vascularization. Heparin induced thrombocytopenia (HIT)
was diagnosed by a positive serum anti-platelet factor four
antibody in association with 50% reduction in baseline
platelet count while being exposed to heparin products.
Any wound with purulent drainage, erythema, or indura-
tion that required an alteration of postoperative patient
management such as opening of the surgical incision or
initiation of antibiotic treatment constituted a wound in-
fection.
Outcome measures of serum creatinine (mg/dL), sys-
tolic (SBP) and diastolic (DBP) blood pressure (mmHg),
and the number of anti-hypertensive medications were
evaluated at hospital discharge or the first postprocedural
exam within 30 days of the revascularization, at approxi-
mately one year follow up and at the most recent ( one
year) follow up exam. Blood pressure outcomes were eval-
uated using standard reporting criteria and summarized as
follows:20 A cure of hypertension is defined as a systolic
blood pressure (SBP) less than 140 mmHg and diastolic
blood pressure of less than 90 mmHg without use of
anti-hypertensive medications. An improvement in blood
pressure is defined as SBP  140 mmHg or DBP  90
mmHg on the same number of anti-hypertensive medica-
tions as required preintervention, or a decrease in the DBP
of15 mmHg on the same or fewer BP medications. Lack
of blood pressure benefit is an increase in SBP or DBP or
the number of medications, or anyone not fulfilling criteria
for cure or improvement. Definitions of renal function
outcomes include a cure defined as a reduction of 20% or
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defined as a change within 20% of baseline creatinine and
failure of renal function response is defined as an increase of
20% or more from the baseline preintervention creatinine
level.
Long-term outcomes studied were survival, primary
graft patency, assisted graft patency, freedom from reinter-
vention, and freedom from dialysis in accordance with SVS
reporting criteria.21 Patients with recurrent stenosis (0%-
60%) without reintervention were included as patent in the
primary patency calculations, while those developing severe
stenosis ( 60%) or those in which reintervention was
performed were classified as loss of primary patency. Pa-
tients who developed end stage renal disease in the absence
of anatomic data to refute loss of graft or stent patency or
those with graft/stent occlusion on follow up imaging were
evaluated as graft failures. Long-term survival data from the
Social Security Mortality Database was gathered using pa-
tient Social Security Numbers.
All demographic data are presented as percent preva-
lence in the study populations. All mean data is presented as
mean  standard deviation (sd). Statistical analysis was
performed by using two-tailed t tests for continuous vari-
ables and chi-square analysis for categorical data. Long-
term survival, primary patency, freedom from intervention,
and freedom from dialysis data was evaluated by Kaplan
Meier analysis. The log rank test for the equality of the
survival distribution curves was used to evaluate for
differences in survival, primary patency, freedom from
intervention, and freedom from dialysis. Univariate and
multivariate regression analyses were performed to identify
Table I. Demographics
Percutan
N 
%
Age (range) 72  9
Gender: male 58% (1
Preoperative creatinine (mg/dL) (range) 1.8  1
Peripheral vascular disease 38% (7
Coronary artery disease 51% (1
Smoker 29% (5
Diabetes 21% (4
Hypertension 95% (1
Chronic renal insufficiency 50% (9
Hypercholesterolemia 80% (1
Acute renal failure 7% (1
Mean preoperative systolic BP (range) 150  24
Mean preoperative diastolic BP (range) 75  13
Mean # BP medications (range) 1.9  1.
Follow up
Mean follow-up (days) 614  54
Median follow-up (days) 5
Indication for revascularization
Hypertension 46% (9
Renal salvage 54% (1
BP, Blood pressure.
Bolded P values in tables denote statistically significant values.predictors of improvement or cure of renal dysfunction andhypertension. Results with a P  .05 were considered
statistically significant. Statistical analysis of the data was
performed by a statistician using SPSS version 15.0 (SPSS,
Inc, Chicago, Ill).
RESULTS
The demographic and clinical features of the study
population as a function of mode of revascularization are
displayed in Table I. Patients undergoing open revascular-
ization were more likely to be younger, have a higher
baseline creatinine, and weremore likely to have a history of
peripheral vascular disease. Baseline SBP and DBP were
similar in the two groups; however, OR patients were on a
greater number of anti-hypertensive medications prior to
revascularization. Long-term follow up was similar in the
two groups (Table I).
Percutaneous revascularization required angioplasty
alone in 2.9% (6/203), angioplasty and stenting in 76%
(154/203) and bilateral angioplasty and stenting in 22%
(44/203) of patients. Technical success, as defined by less
than 30% residual stenosis following intervention, was 99%
(201/203). Open renal artery revascularization involved
endarterectomy in 47% (21/47) and bypass in 53% (26/
47) of patients. Bilateral revascularization was performed in
43% (20/47) of OR patients and concomitant aortic sur-
gery was performed in 32% (15/47) of patients. Technical
details of renal artery revascularization are presented in
Table II.
Perioperative complications were more likely to occur
in individuals undergoing open renal artery revasculariza-
tion, wherein 77% (36/47) of patients undergoing OR did
(PR) Open (OR)
N  47
% (N) P
8) 65  11 (36-83) <.001
03) 55% (26/47) .7
.5) 2.2  1.6 (0.7-7.7) .03
3) 75 (35/47) <.001
03) 64 (30/47) .1
3) 21% (10/47) .3
3) 13 (6/47) .2
03) 94 (44/47) .7
3) 51% (24/47) .9
03) 85% (40/47) .4
3) 13% (6/47) .2
240) 155  26 (105-233) .2
130) 77  13 (57-122) .2
) 2.3  1.2 (0-5) .02
2094) 774  760 (1-2418) .09
533
3) 51% (24/47) .6
03) 49% (23/47)eous
203
(N)
(25-8
19/2
(0.6-5
6/20
03/2
8/20
2/20
92/2
9/20
62/2
4/20
(90-
(46-
2 (0-5
0 (1-
45
5/20
09/2not develop any postoperative complications compared
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Patients undergoing PR developed contrast nephropathy in
4.4% (9/204) and access site pseudo aneurysm in 1.5%
(3/204). Patients treated with OR developed pneumonia
in 4.3% (2/47), heparin induced thrombocytopenia in
4.3% (2/47), and wound infection in 4.3% (2/47). There
were no perioperative myocardial infarctions identified in
this patient group. Postoperative death occurred in one
patient in each group (Table III).
Baseline systolic and diastolic blood pressure was not
statistically different in patients undergoing PR and OR.
SBP and DBP were 150 24 mmHg and 74 13 mmHg
in PR patients and were 160  26 mmHg and 77  13
mmHg in OR patients, respectively (P  .3). SBP im-
proved in both groups and was similar at one year (PR
SBP/DBP of 130  20 mmHg/69  11 mmHg; OR
SBP/DBP of 130  16 mmHg/77  11 mmHg [P  .9
for SBP, P  .7 for DBP]; Table IV) At the first post
procedure follow up, 76% (123/162) of PR patients and
90% (38/42) of OR patients (P .1) were found to have a
clinical cure or improvement in their blood pressure. Cure
or improvement in blood pressure was not statistically
different in both groups (74% PR vs 89% OR; P  .2) at
Table II. Technical details
Percutaneous (PR)
Primary intervention 91% (203/224)
Contrast volume 83  58 (2-405)
Angioplasty only 2.9% (6/203)
Angioplasty and stent 75% (153/203)
Bilateral angioplasty and stent 22% (44/203)
Success 99% (201/203)
Open (OR)
Endarterectomy 47% (21/47)
Bypass 53% (26/47)
Concomitant aortic surgery 32% (15/47)
Bilateral 43% (20/47)
Aortorenal bypass 65% (17/26)
Hepatorenal bypass 23% (6/26)
Splenorenal bypass 8% (2/26)
Iliorenal bypass 4% (1/26)
Table III. Perioperative complications
Percutaneous (PR)
N  203
% (N)
Open (OR)
N  47
% (N) P
None 88% (179/203) 77% (36/47) .001
Death 0.5% (1/203) 2.1% (1/47)
Hematoma 3.9% (8/203) 2.1% (1/47)
Contrast nephropathy 4.4% (9/203) 0
Pseudoaneurysm 1.5% (3/203) 0
Pneumonia 0 4.3% (2/47)
HIT 0 4.3% (2/47)
Re-exploration for
bleeding 0 2.1% (1/47)
Wound infection 0 4.3% (2/47)
HIT, Heparin induced thrombocytopenia.one-year follow up. Long term blood pressure cure orimprovement was 70% in PR patients and 89% (P  .2) in
patients undergoing OR (Table V).
Baseline serum creatinine was significantly higher in
patients undergoing OR compared with those undergoing
PR (2.2 1.6 vs 1.8 1; P .03). Serum creatinine at the
first, second, and most recent postoperative visits were not
statistically different in OR and PR patients. A benefit in
serum creatinine was appreciated in patients undergoing
OR with a decrease in serum creatinine from 2.2  1.6 at
baseline to 1.7  1.6 (P  .001; Table IV) Renal function
was more likely to improve (45% OR vs 17% PR; P .001)
at the first and one-year follow up (52%OR vs 24% PR; P
.001) evaluations in OR compared with PR. At one-year
follow up, 83% of PR and 87% ofOR patients were found to
have stable or improved renal function. Long term renal
salvage results showed stable or improved renal function in
76% of PR and 86% of OR (P .1) patients (Table VI). In
patients presenting with acute renal failure requiring hemo-
dialysis, OR was more likely to result in a cure (P  .01),
with 83% (5/6) OR vs 14% (2/14) PR patients removed
from renal replacement therapy. The absolute creatinine
decrease from pre-operative to one-year follow up was
greater in ESRD patients treated with OR (3.0  2.1
[4.8 to 1.2] OR vs 0.73  1.4 [2.8 to 1.9];
P  .02).
Indication specific outcomes showed that patients un-
dergoing OR were more likely to have cure or improve-
ment in hypertension at one-year follow up (100% OR vs
73% PR; P  .04) when undergoing renal artery revascu-
larization for treatment of hypertension. PR and OR re-
sulted in rates of cure or improvement in renal salvage at
one-year follow up (75% PR vs 78% OR; P  .7) that were
not statistically different when undergoing renal artery
revascularization for hypertension (Table VII). At one year
follow up, renal function was improved or stable in more
patients undergoing OR than PR (90% OR vs 77% PR; P
.001) for the treatment of hypertension. The rate at which
renal function improved or remained stable was not statis-
tically different in the two groups (86% PR vs 85% OR; P
.4) at one year when renal artery revascularization was
performed for the indication of renal salvage (Table VIII).
Long-term anatomic information was available in 116
PR and 14OR patients including renal artery duplex, CTA,
MRA, or DSA. Recurrent stenoses of any degree were
identified in 27% (31/116) PR patients and 7% (1/14) OR
patients (P  .2) and were characterized as severe (60%-
99%) in 19% (22/116) PR and 7% (1/14) OR patients. As
a result of severe restenosis or restenosis with clinical se-
quelae requiring a secondary intervention, graft or stent
occlusion, or progression to ESRD without anatomic data
to refute loss of graft patency in the long term, primary
patency (Fig 1) was lower (P  .05) in PR patients at one
(93% 2% PR vs 97% 3%OR) and three years (84% 4%
PR vs 91% 6%OR). Long-term outcomes showed similar
survival, assisted primary patency, freedom from interven-
tion, and freedom from dialysis in patients with PR andOR.
Despite differences in primary patency, the secondary pa-
tency and freedom from re-intervention plots were similar
Most recent 69  11 [43-100]; n  91
Failure 27% (20/75) 12% (2/17)
Failure 24% (22/90) 14% (2/14)
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reintervention in patients with progressively increasing ste-
nosis or the development of rising creatinine or worsening
Open (OR)
N  47 P
2.2  1.6 [0.7-7.7]; n  45 .03
1.6  0.9 [0.6-6.1]; n  45 .6
1.7  0.8 [1.0-4.0]; n  29 .6
1.7  0.7 [0.8-3.3]; n  14 .4
160  26 [105-233]; n  45 .3
130  14 [90-168]; n  42 .9
130  16 [102-175]; n  37 .9
130  22 [100-180]; n  19 .9
77  13 [57-122]; n  45 .2
67  7 [50-80]; n  42 .2
70  11 [50-92]; n  37 .7
65  10 [50-85]; n  19 .2
Table VII. Indication specific clinical outcomes: blood
pressure control ( one year)
Percutaneous (PR)
N  204
% (N)
Open (OR)
N  47
% (N) P
Hypertension as
indication
Cure 6.3% (4/63) 11% (2/18) .04
Improvement 67% (42/63) 89% (16/18)
Failure 27% (17/63) 0
Renal salvage as
indication
Cure 11% (8/75) 5.6% (1/18) .7
Improvement 64% (48/75) 72% (13/18)
Failure 25% (19/75) 22% (4/18)
Table VIII. Indication specific clinical outcomes: renal
function ( one year)
Percutaneous (PR)
N  204
% (N)
Open (OR)
N  47
% (N) P
Hypertension as
indication
Improvement 7.6% (5/66) 50% (5/10) .001
Stable 70% (46/66) 40% (4/10)
Failure 23% (15/66) 10% (1/10)
Renal salvage as
indication
Improvement 37% (30/81) 53% (10/19) .4
Stable 49% (40/81) 32% (6/19)
Failure 14% (11/81) 16% (3/19)Table IV. Creatinine and blood pressure results
Percutaneous (PR)
N  204
Creatinine
Pre-op 1.8  1 [0.6-5.5]; n  199
 30 days post-op 1.7  0.9 [0.6-6.8]; n  199
 1 year post-op 1.8  1.1 [1.0-7.0]; n  151
Most recent 1.9  1.1 [0.6-5.8]; n  90
Systolic blood pressure
Pre-op 150  24 [90-240]; n  217
 30 days post-op 130  20 [40-200]; n  195
 1 year post-op 130  20 [95-225]; n  160
Most recent 130  20 [102-214]; n  91
Diastolic blood pressure
Pre-op 74  13 [43-130]; n  217
 30 days post-op 70  11 [41-100]; n  195
 1 year post-op 69  11 [30-100]; n  160Table V. Clinical outcomes: blood pressure control
Percutaneous (PR)
N  204
% (N)
Open (OR)
N  47
% (N) P
Post-op exam #1
 30 days post-op
Cure 6.8% (11/162) 7.1% (3/42) .1
Improvement 69% (112/162) 83% (35/42)
Failure 24% (39/162) 9.5% (4/42)
Post-op exam #2
 1 year post-op
Cure 8.7% (12/138) 8.3% (3/36) .2
Improvement 65% (90/138) 81% (29/36)
Failure 26% (36/138) 11% (4/36)
Post-op exam #3
Most recent
Cure 5.3% (4/75) 0 .2
Improvement 68% (51/75) 88% (15/17)Table VI. Clinical outcomes: renal function
Percutaneous (PR)
N  204
% (N)
Open (OR)
N  47
% (N) P
Post-op exam #1
 30 days post-op
Improvement 17% (32/192) 45% (19/42) <.001
Stable 72% (139/192) 52% (22/42)
Failure 11% (21/192) 2.4% (1/42)
Post-op exam #2
 1 year post-op
Improvement 24% (35/147) 52% (15/29) .009
Stable 59% (86/147) 35% (10/29)
Failure 18% (26/147) 14% (4/29)
Post-op exam #3
Most recent
Improvement 19% (17/90) 43% (6/14) 0.1
Stable 57% (51/90) 43% (6/14)renal function and not the mere presence of stenosis alone
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one year (88% 2% PR vs 90% 5%OR; P .9) and three
Fig 1. Primary Patency. KaplanMeier curves plotting the fraction
of grafts or stents patent or free of critical stenosis over time. The
solid line represents patency in patients treated with open surgical
renal artery revascularization and the dashed line represents the
patency of endovascular revascularization. Arrows delineate when
the standard error exceeds 10%.
Fig 2. Survival. Kaplan Meier curves plotting the fraction of the
study population alive over time. The solid line represents survival in
patients treated with open surgical renal artery revascularization and
the dashed line represents the survival of patients treated endovascu-
larly. Arrows delineate when the standard error exceeds 10%.years (72%  4% PR vs 71%  9% OR; P  .9; Fig 2).Assisted primary patency was not statistically different (P
.6) at one (94% 1% PR vs 95% 4% OR) and three years
(96%  2% PR vs 95%  4% OR; Fig 3). One year (97% 
1% PR vs 97%  3% OR) and three year (93%  2% PR vs
91%  7% OR) freedom from reintervention was not
statistically different (P  .8) for PR and OR (Fig 4).
Dialysis-free survival was not statistically different at one
year (85% 3% PR vs 85% 6% PR) and 3 years (72% 4%
PR vs 69%  9% PR; P  .7; Fig 5).
Multivariate analysis identified three factors predicting
improvement in blood pressure, including the number of
blood pressure medications required at baseline, presence
of diabetes, and open renal artery revascularization; how-
ever, only the number of baseline BP meds remained an
independent predictor (Odds Ratio [OR] 1.5; 95% Confi-
dence Interval [CI] 1.2-1.9) of an improved blood pressure
at one year follow-up. An improved creatinine at one year
was independently predicted by renal salvage as the indica-
tion for revascularization (OR 3.6; 95% CI 1.6-8.2), open
renal artery revascularization (OR 2.4; 95% CI 1.1-5.5),
and baseline serum creatinine (OR 1.6; 95% CI 1.2-2.1). A
benefit in renal function, including improved or stable
creatinine at one-year follow up was predicted by renal
salvage as indication, open revascularization, and number
of blood pressure medications required at baseline; how-
ever, only renal salvage as an indication for revasculariza-
tion (OR 1.8; 95% CI 1.1-3.1) remained an independent
predictor on multivariate analysis. Long term mortality was
Fig 3. Assisted Primary Patency. Kaplan Meier curves plotting
the fraction of grafts or stents patent over time. The solid line
represents patency in patients treated with open surgical renal
artery revascularization and the dashed line represents the patency
of endovascular revascularization. Arrows delineate when the stan-
dard error exceeds 10%.predicted by renal salvage as an indication for revasculariza-
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disease, and chronic renal insufficiency; however, only renal
salvage as a procedural indication (OR 2.5; 95% CI 1.2-
5.2) and a previous history of CAD (OR 3.1; 95% CI
1.5-6.2) remained independent predictors of death. No
independent predictors of progression to end stage renal
disease were identified.
DISCUSSION
Atherosclerotic renal artery stenosis is a progressive
disease commonly found in the elderly.4 The clinical se-
quelae of RAS are varied and overlap with parenchymal
renal disease, confounding the clinical presentation as well
as the study of focused outcomes such as blood pressure
control and renal salvage following intervention for renal
artery stenosis. Despite a relatively weak evidence base
supporting percutaneous renal artery angioplasty for renal
artery stenosis, the advent of percutaneous methods for
renal artery revascularization has led to a proliferation in the
number of endovascular renal artery interventions in recent
years.12,23 Indeed, our practice reflects the national trend
wherein stent revascularization is more frequently utilized
except in cases requiring concomitant aortic reconstruc-
tion, those with unfavorable renal artery anatomy, or in
young patients with advanced disease necessitating a more
durable reconstruction.
Atherosclerotic renal artery disease is associated with a
Fig 4. Freedom from Reintervention. Kaplan Meier curves plot-
ting the fraction of grafts or stents requiring an intervention to
maintain patency or reverse clinical deterioration. The solid line
represents reintervention in patients treated with open surgical
renal artery revascularization and the dashed line represents rein-
tervention in patients treated endovascularly. Arrows delineate
when the standard error exceeds 10%.number of cardiovascular comorbidities. Patients with RASare older and are more likely to have concomitant periph-
eral arterial and coronary artery disease, as well as other
systemic risk factors for atherosclerosis.1-3 Our patient pop-
ulation was noted to have rates of peripheral arterial disease,
hypertension, diabetes mellitus, chronic renal insufficiency,
and hypercholesterolemia that were comparable to other
studies. Our current report emphasizes the role of coronary
artery disease on long term outcomes in this patient popu-
lation as reported in our earlier publications as well as
others.2,7,21 Coronary artery disease was present in 53% of
all patients, and the presence of CAD was identified as an
independent predictor of long term mortality (OR 3.1;
95% CI 1.5-6.2).
Initially, percutaneous renal artery revascularization
was limited by reduced technical success and patency in
comparison to open surgical revascularization, likely due to
the use of angioplasty alone, with larger, less flexible de-
vices, and inferior procedural imaging. However, recent
reports, including this series, note an increase in technical
success and assisted patency.11,23,24 In the current study,
OR was associated with a 7% rate of severe long term
restenosis and PR was associated with a 19% rate of
severe restenosis, in keeping with previously published
reports.6-11 The morbidity and mortality of percutaneous
renal artery revascularization is markedly reduced in com-
parison to open renal artery revascularization as shown by
several groups.23,24 Our findings reflect this consensus,
Fig 5. Dialysis-free Survival. Kaplan Meier curves plotting the
fraction of the study population alive and with preserved renal
function over time. The solid line represents freedom from dialysis
in patients treated with open surgical renal artery revascularization
and the dashed line represents the freedom from dialysis in patients
treated endovascularly. Arrows delineate when the standard error
exceeds 10%.with 12% of PR patients developing an adverse post proce-
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OR. The increased technical success, improved long term
assisted patency, and limited morbidity has resulted in an
increase in referrals for percutaneous renal artery revascu-
larization and an evolution of our practice with themajority
of renal artery revascularizations performed using percuta-
neous methods. Two previous publications of our experi-
ence with renal artery revascularization reported on 235
patients undergoing OR over a 20 year period.6,7 In com-
parison, this report represents 251 primary renal revascu-
larization procedures performed over a four-year period
with 81% PR reflecting a five-fold increase in referrals for
less invasive renal artery revascularization.
The benefit in blood pressure response following per-
cutaneous renal artery intervention has been unclear due to
the discordant outcomes from several small randomized
controlled trials of renal artery angioplasty.13-15 The largest
of these trials, the Dutch Renal Artery Stenosis Interven-
tionCooperative Study (DRASTIC), included 106 patients
with 50% renal artery stenosis, serum creatinine  2.3
mg/dL, and diastolic blood pressure  95 mmHg who
were randomized to percutaneous renal artery angioplasty
or to rigorous drug therapy.15 On an intention to treat
analysis, the study found similar reductions in blood pres-
sure in both treatment arms, noting little to no clear
advantage of renal artery angioplasty in comparison to
medical therapy. However, the significant 44% crossover of
medically treated patients into the angioplasty arm of the
study demonstrates the inability to control blood pressure
with pharmacotherapy alone. In addition, this study is of
historical interest only, as primary PTA is not state-of-the-
art for endovascular renal revascularization, as our series
demonstrates (97% underwent PTA and stent deploy-
ment). Despite their conclusion of no benefit in blood
pressure control using mean blood pressure following renal
artery angioplasty, the DRASTIC investigators found that a
favorable effect of angioplasty was identified when out-
comes were evaluated according to blood pressure re-
sponse. They found that blood pressure control was cured
in 7%, improved in 68%, and worse in 9% of patients
undergoing renal artery angioplasty compared with 0%
cure, 38% improved, and 33% failure with medical therapy
alone. Using the standard reporting criteria defined by
Rundback et al, our renal artery revascularization experi-
ence resulted in similar rates of cure in blood pressure in
8.7% of PR patients and 8.3% of OR and an improvement in
blood pressure control in 65% of PR and 83% of OR
patients at one-year follow up. We found no statistically
significant difference in blood pressure outcomes between
percutaneous and open revascularization techniques; how-
ever, when evaluating the likelihood of blood pressure
control when blood pressure control was the indication for
renal artery revascularization, we found OR to have im-
proved results compared with PR. The blood pressure
responses to both OR and PR in the present study concur
with those of previously published reports using OR
alone6-9 and PR10,15,22 alone. Our findings are improved
from outcomes of percutaneous revascularization pre-sented by several investigators and may represent an evolu-
tion in technique and technology, as ours is a more con-
temporary series.17,24-26 Our previously reported criteria
for intervention for renal artery stenosis (75% stenosis)
may have led to selection of patients more likely to benefit
from renal artery revascularization.6
Open renal artery revascularization results in significant
and durable renal salvage and dialysis free survival as shown
by our previous publications and those of others.6,7,9 Our
current report highlights the success and durability of open
renal artery revascularization, as OR patients were more
likely to exhibit an improvement in serum creatinine at the
first postoperative visit and at one-year follow up compared
with patients treated with PR. Using similar criteria for
renal salvage, Cherr and coworkers found improved renal
function following surgical renal artery revascularization in
43%, stable function in 47%, and deterioration in 10%,
similar to our findings of 53%, 35%, and 14% for the same
outcomes, respectively. PR in our hands resulted in 24%
improved, 58% stable, and 18% worse renal function at one
year compared with baseline. These findings were similar to
those of others;24,26 however, contrary to our findings,
Zeller and coworkers found that 52% of patients undergo-
ing renal artery stenting were found to have an improve-
ment in renal function at one year despite similarities in
patient populations (with the exception of a higher inci-
dence of diabetes in their cohort).17 While renal function
was not a primary endpoint of the trial, the DRASTIC
investigators noted that patients who were medically
treated suffered a 16% renal artery occlusion rate and dete-
rioration of renal function in 12% at one year.15 When
further evaluating the success of renal artery revasculariza-
tion for the indication of renal salvage, we found that the
results of both OR and PR were not statistically different
when evaluating the combined results of improved or stable
renal function. Indeed, renal salvage as an indication for
renal artery revascularization independently predicted the
likelihood of improved or stable renal function at one year
of follow up regardless of the modality of revascularization.
This is reflected in the low number of our patients progress-
ing to end stage renal disease resulting in a dialysis free
survival of 75% at three to four years follow up in our
hands following PR or OR similar to that of Cherr and
coworkers for OR.8 This is an important clinical outcome
in light of the long term increase in cardiovascular and all
cause mortality associated with worsening renal function
and the dismal long term survival of patients with renal
vascular disease progressing to end stage renal disease.11,27
A major limitation of our study includes the retrospec-
tive nature of the study leading to potential observational
and selection biases. The use of serum creatinine as a
surrogate for renal function was a direct result of the
retrospective nature of the study. Serum creatinine values
are a reflection of patient body mass and can be affected by
numerous factors including hydration status, protein turn-
over, changes in body mass, and medications, to name a
few. Prospective collection of necessary data to calculate
creatinine clearance or glomerular filtration rate at more
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tional biases. Other observational biases inherent to our
study relate to our practice at a tertiary medical center. As
such, our patient population consists of a large number of
patients referred from long distances away. The population
of patients treated in our practice and conclusions drawn
from our data may not be applicable to all patients, and,
additionally, patients choosing to follow up elsewhere re-
sult in a loss of late outcomes data and resultant observa-
tional biases. Our study is unique in evaluation of renal
artery revascularization outcomes based on indication for
intervention. Renal artery disease, however, presents along
a clinical spectrum and categorization of intervention into
two discrete indications may have introduced selection
biases. Lastly, the retrospective nature of the study resulted
in a discordant number of patients in the two study groups.
This discrepancy in patient numbers was further com-
pounded by our study methods. The evaluation of out-
comes using indications further compartmentalized the
patient populations into more groups, resulting in small
numbers of patients evaluated at late follow up and increas-
ing the likelihood of statistical errors. While our patient
cohorts are small, there are a number of statistically signif-
icant observations that we have found that are of value for
discussion and further investigation. Study limitations
could have been avoided with the use of prospectively
gathered or randomized data; however, our results do
mirror the work of others as discussed and the findings of a
yet unpublished randomized trial comparing open and
percutaneous renal artery revascularization.28
Ours is a unique study comparing the outcomes of
renal artery revascularization using both open and percuta-
neous methods and evaluating both endpoints of blood
pressure control as well as preservation of renal function.
We evaluated our data in clinically relevant outcome mea-
sures. To that end, our results show that open and percu-
taneous revascularizations are similarly efficacious and ben-
efit patients with hypertension associated with renal artery
stenosis. Immediate and long-term clinical outcomes favor
open revascularization for preservation of renal function.
This advantage of OR likely imparts from selection bias
resulting in the triage of young patients with more ad-
vanced disease who are more likely to benefit from renal
artery revascularization to OR. Long-term survival and
dialysis-free survival are independent of the modality of
revascularization. Despite the durability and renal salvage
advantages of open surgery, the attendant morbidity and
mortality of open renal artery revascularization ensures a
significant role for percutaneous intervention for renal ar-
tery stenosis in most patients. Nonetheless, in skilled hands,
there will continue to be a role for open renal revascular-
ization in selected individuals.
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